论文部分内容阅读
目的:评价甲氨蝶呤与来氟米特联用治疗类风湿关节炎患者的临床疗效和安全性。方法:选取2015年1月—2016年1月间收治的类风湿关节炎患者106例,将其分成观察组和对照组,每组53例;对照组患者均给予甲氨蝶呤治疗,观察组患者在对照组基础上加用来氟米特治疗,治疗3月后比较两组患者晨僵时间、关节压痛指数、关节肿胀指数等临床症状,并检测治疗前后血细胞沉降率(ESR)、C-反应蛋白(CRP)、白细胞介素(IL)-1β、IL-6及肿瘤坏死因子(TNF)-α的表达水平,以及不良反应的发生情况。结果:两组患者治疗后各临床症状指标均低于治疗前(P<0.05);两组患者治疗前ESR、CRP、IL-1β、IL-6和TNF-α等经组间比较其差异无统计学意义(P>0.05),观察组患者治疗后各血清学检测指标均低于对照组(P<0.01)。结论:采用甲氨蝶呤与来氟米特治疗类风湿关节炎患者的疗效优于单用来氟米特的疗效。
Objective: To evaluate the clinical efficacy and safety of methotrexate combined with leflunomide in patients with rheumatoid arthritis. Methods: 106 patients with rheumatoid arthritis who were admitted between January 2015 and January 2016 were divided into observation group and control group, with 53 cases in each group. Patients in the control group were treated with methotrexate, and the observation group The patients were treated with leflunomide on the basis of the control group. The clinical symptoms such as morning stiffness, joint tenderness index and joint swelling index were compared between the two groups after 3 months of treatment. The ESR, Reactive protein (CRP), interleukin (IL) -1β, IL-6 and tumor necrosis factor (TNF) -α, as well as the incidence of adverse reactions. Results: The indexes of clinical symptoms in both groups after treatment were lower than those before treatment (P <0.05). There was no significant difference in ESR, CRP, IL-1β, IL-6 and TNF-α among the two groups before treatment Statistical significance (P> 0.05), the observation group patients after treatment serological test indicators were lower than the control group (P <0.01). CONCLUSIONS: Methotrexate and leflunomide are superior to leflunomide in the treatment of patients with rheumatoid arthritis.